Unclear.: This single gain-of-function point mutation in jak2 has been identified in 95 to 97 percent of patients with polycythemia vera (pv), 23 to 75 percent of those with essential thrombocytosis (et), and 43 to 57 percent of those with primary myelofivrosis (pmf).
Answered 1/30/2014
4.8k views
3 doctors weighed in across 2 answers
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question